Sign in

Robert James Labick

Research Analyst at CJS Securities

Robert James Labick is President and Director of Research at CJS Securities, specializing in small- and mid-cap equity research with comprehensive sector coverage that includes companies such as Knowles, Helen of Troy, Balchem, and NEOG. He has set notable price targets and provided actionable insights for these firms, with his recent NEOG target reflecting timely sector expertise and buy-side integration. Labick began his career in 1996 at PaineWebber, later joining Evergreen Investments before moving to CJS Securities as Senior Analyst in 2002, advancing to Director of Research in 2006, and becoming President in 2015. Professionally accredited, he is FINRA-registered with 28 securities licenses and maintains a 24-year track record across three major firms.

Robert James Labick's questions to BALCHEM (BCPC) leadership

Question · Q3 2025

Robert James Labick asked about the drivers behind the accelerated growth in Balchem's food ingredients and solutions business, particularly in the context of 'better-for-you' trends, and the outlook for its subsegments in 2026. He also inquired about the current stage of market penetration for key nutrient minerals like choline, K2, MSM, and magnesium, and the remaining runway for growth and awareness.

Answer

Chairman, President, and CEO Ted Harris explained that the Human Nutrition and Health segment performed strongly, with the nutrient portfolio growing 30% and food ingredients up almost 7%. He attributed the food business's growth to 'better-for-you' trends, citing examples like high-protein snacks (meat sticks, ZCRISPs), high-fiber nutritional beverages addressing GLP-1 drug side effects, and less processed foods. He expects these trends to continue driving higher growth. Regarding nutrient minerals, Mr. Harris stated there's a significant runway for growth, as most of their portfolio is not well-known, with market opportunities estimated at 3-4x current size. He sees strong double-digit growth continuing through two vectors: replacing less bioavailable minerals and driving new users.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts